Purpose: This study intended to explore the contribution of CYP4F2 1347C>T and GGCX 12970C>G polymorphisms on warfarin dose requirements among Sudanese subjects.
Methods: A total of 136 Sudanese patients of heart valve replacement receiving stable warfarin dose were recruited for this study. Blood samples were collected; DNA was extracted using phenol chloroform method. Genotyping for CYP4F2 1347C>T and GGCX 12970C>G polymorphisms was performed using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method. The association of genotype with warfarin dose requirement was measured by Kruskal Wallis and Mann Whitney U tests. Genotype, age, gender, comorbidity and concurrent medication were tested as predictors of stable warfarin dose using univariate regression analysis. For all tests, p. values < 0.05 were considered statistically significant.
Results: Frequencies of CYP4F2 1347C>T genotypes were 22.8% CC, 61% CT and 16.2% TT. The frequencies of C, T alleles were 0.533, 0.466 respectively which are deviated from Hardy Weinberg equilibrium (p. value = 0.008). Regarding GGCX 12970C>G genotyping, 96.9% were CC and 3% were CG. The frequencies of C, G alleles were 0.984 and 0.015 respectively which are in accordance with Hardy Weinberg equilibrium (p. value = 0.859). Insignificant differences in the mean daily warfarin dose between different genotype groups were observed (all p. values > 0.05). None of the studied variables was significant predictor of stable warfarin dose in this study population (p. values > 0.05).
Conclusion: No significant contribution of CYP4F2 1347C>T and GGCX 12970C>G polymorphisms on warfarin dose requirements was observed in this study population.